One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
Alimentary Pharmacology & Therapeutics2012Vol. 37(2), pp. 204–213
Citations Over TimeTop 10% of 2012 papers
William J. Sandborn, J F Colombel, Geert D’Haens, Gert Van Assche, Douglas C. Wolf, Martina Kron, A. Lazar, Anne Robinson, Mei Yang, J. Chao, Roopal Thakkar
Abstract
Adalimumab treatment was associated with a positive benefit/risk balance in the overall population of patients with moderately-to-severely active ulcerative colitis in ULTRA 2; early response was predictive of a positive outcome at 1 year (NCT00408629).
Related Papers
- → THU0211 Six months after treatment discontinuation tnf is still in complex with adalimumab(2018)1 cited
- → FRI0165 A prediction tool for drug monitoring of adalimumab in rheumatoid arthritis.(2013)
- 강직성 척추염 환자에서 Adalimumab 치료 후 관찰된 천장관절염의 회복 1예 Running title: 강직성 척추염에서 Adalimumab 치료와 천장관절염의 회복(2012)
- → Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial(2023)